DBV Technologies at the H.C. Wainwright Conference
DBV Technologies, a biopharmaceutical company in the clinical stage, is focused on creating innovative treatments for food allergies and immunologic conditions. The company's CEO, Daniel Tassé, is set to provide valuable insights during a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference.
Event Details
This conference will take place in New York City, serving as a platform to discuss the latest advancements in the biopharmaceutical industry. Tassé's presentation is scheduled for a specific day and will be accessible via a live webcast for those who are unable to attend in person. Additionally, a replay of the presentation will be available for 90 days after the event, allowing stakeholders to engage with the material at their convenience.
About DBV Technologies
DBV Technologies is committed to addressing significant medical needs, especially in the area of food allergies. These allergic reactions can differ greatly in severity and impact millions around the world, particularly young children. Utilizing its VIASKIN® patch technology, the company aims to introduce small doses of allergenic substances to help modify the immune system's response.
Understanding VIASKIN® Patch Technology
This cutting-edge delivery method employs epicutaneous immunotherapy (EPIT) to improve tolerance to allergens through the skin. By re-educating the immune system, the VIASKIN® patch aims to reduce the severity of allergic reactions over time. Current clinical trials are focusing on young children who suffer from peanut allergies.
DBV Technologies' Commitment
The company is dedicated to transforming the management of food allergies. With offices located in France and North America, DBV Technologies is well-positioned for growth and significant impact in this vital health area. Their ordinary shares are publicly traded under the ticker DBV on Euronext Paris, while their American Depositary Shares (ADSs) are available on the Nasdaq under the ticker DBVT.
Staying Informed
For those looking for more information about DBV Technologies and its initiatives, the company has a strong online presence. Interested individuals can easily visit the corporate website for updates on events and developments. Additionally, engaging through social media platforms offers further opportunities for connection and information sharing.
Contact Information
If you have any inquiries regarding investment opportunities or media relations, please reach out to the following contacts:
Investor Contact: Katie Matthews
Email: katie.matthews@dbv-technologies.com
Media Contact: Angela Marcucci
Email: angela.marcucci@dbv-technologies.com
Frequently Asked Questions
What is the purpose of DBV Technologies' participation at this conference?
The company's participation is intended to showcase its innovative efforts in tackling food allergies and to engage with investors and stakeholders in the biopharmaceutical field.
What technology does DBV utilize for treating food allergies?
DBV employs a proprietary approach that features its VIASKIN® patch technology, which is designed for epicutaneous immunotherapy (EPIT) to help retrain the immune system.
Where is DBV Technologies headquartered?
The company is based in Châtillon, France, and also has operational facilities in Warren, New Jersey, in North America.
How can I access the conference presentation?
The presentation will be available through a live webcast, and a replay can be accessed on the company's website for 90 days following the event.
What are the ticker symbols for DBV Technologies?
DBV Technologies' ordinary shares are traded on Euronext Paris under the ticker DBV, while its American Depositary Shares (ADSs) are listed on Nasdaq under the ticker DBVT.
